4L Data brand architecture
One naming rule that has absorbed about twenty products, units, acquisitions and partners without rework. 4L Data is a healthcare AI company with one detection technology inside many products. I wrote its brand architecture and built the identity system from it. The technology got its own name, Integr8 AI, and about a third of customer organizations now license it under that name.
Give 4L Data one brand structure for the company, its products and its patented AI, with a rule that settles every naming question after it.
One naming rule that has absorbed about twenty products, units and partners without rework, and a technology brand, Integr8 AI, that about a third of customers now license by name.
Client: 4L Data, a healthcare AI company. Scope: the company brand, the Integr8 AI technology brand, and every product, operating unit and partner mark under them.
My role: I led the architecture strategy and designed the logo and endorsement system that implemented it.
Results: One structure, written once, that has absorbed roughly twenty additions without rework. The technology is now licensed under its own name by about a third of customer organizations.
Each 4L Data product arrived with its own name and logo treatment, and nothing told a buyer how the products related to each other or to the company. A payer evaluating one product could not tell whether the others ran on the same platform or came from the same company. In healthcare technology the buyer is underwriting a multi-year relationship with an organization, and a portfolio that reads as unrelated tools gets discounted across every one of them.
Three things were missing: a rule for when a product earned its own identity, a way to express the shared technology under the products, and a structure for partners and acquired technology, which were arriving faster than anyone could name them.
I evaluated five models against how this business sells: branded house, sub-brand, endorsed, house of brands and hybrid. Then I threw out the scorecard, because a scorecard produces a winner and hides the trade-off inside the weights, and replaced it with four questions. A product earns its own identity when it sells to a different buyer, moves through a different go-to-market motion, or is likely to be licensed, partnered or sold on its own. It stays under the master brand when the buyer is the same, cross-selling is the growth path, marketing resource is finite, and corporate credibility is what the customer is underwriting.
With four questions a product lead reaches an answer in a doc without me, and anyone who disagrees has to argue with a specific question.
The default reading was that the AI is a feature of the flagship product. I argued for treating it the way Qualcomm treats Snapdragon: a technology brand named, marketed and licensed independently of the devices it goes into. A capability buried inside a product is worth what that product is worth. Named and visibly endorsed, it can be licensed, partnered and carried into products the company does not own.
So the architecture has exactly two brand-bearing layers. The company carries trust. Integr8 AI carries the differentiator and the license. Everything else resolves to one of the two, and the naming test decides which.
The property and casualty unit sells to insurance carriers, and their argument was that a master brand built on healthcare credibility is a liability in a room of carrier executives. Under my own test they had a case: different buyer, different motion. I kept them under the master brand anyway, with a distinct product mark and the technology endorsement. A carrier is underwriting the same two things a payer is: whether the detection technology is real and whether the company will still be there in three years. A separate brand would have started that credibility at zero while splitting the budget that proves it.
The cost is permanent. Every product carries a second mark and an endorsement lockup, which takes space and adds an approval step. A team that wants to be the sharpest voice in its own market will always want more room than this gives them.
The portfolio has gone from a handful of products to roughly twenty products, operating units, acquired technologies and equity partners. Each resolves to one of three places: it carries the master brand, it carries its own name with the Integr8 AI endorsement, or it stays independent with the technology inside it. None has required reopening the architecture. About a third of customer organizations now license the technology to resell to their own clients, and that revenue depends on the technology having a name a partner can put in front of its own customers.
One seam is still open. Whether something is an acquisition or an equity partner is a judgment call, the mark changes with the answer, and nobody budgets for the migration when a stake moves. It has not broken anything yet. It is the part I would design differently.